Waltz Quoted on Payment Reporting for Drug & Device Makers

12 April 2017 Bloomberg BNA News
Partner Judy Waltz was quoted in a Bloomberg BNA article, “Drug, Device Markers Could Get Hit for Not Reporting Payments to Doctors,” covering the current and future states of the Open Payments program.

Waltz explained that Open Payments reporting “remains an administrative burden for drug and device manufacturers” but “payment reporting is becoming widespread throughout the health-care industry.” She also explained, as it relates to the future of the program, “the Trump administration has spoken about reducing regulatory burdens, and Open Payments could fit under that category.”

Related Services


New York Expands Pay Equity Law
22 July 2019
Labor & Employment Law Perspectives
The Face of DOL is New, the Name is Not; Trump Picks Scalia for Secretary of Labor
22 July 2019
Labor & Employment Law Perspectives
A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Cloud security inadequate for Cyber threats, are you surprised?
19 July 2019
Internet, IT & e-Discovery Blog
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ